VPT:CC - Ventripoint Announces Sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
(TheNewswire)
Toronto, Ontario – The Newswire –April 25, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTCQB:VPTDF) is pleased to announce its sponsorship of the56th Annual Meeting of the Association for European Paediatric andCongenital Cardiology (AEPC) being held on April 26 th -29 th 2023 inDublin, Ireland.
The AEPC is a network of specialists in the paediatricand congenital cardiology field who strive to promote the sharing ofinformation and resources within the community. The AEPC is currentlyone of the largest global associations in the cardiac field with over1,000 paediatric cardiologists. We are excited to be part of thishighly specialized group of people to demonstrate how our productsenhance cardiac care.
This year’s theme is “ BuildingBridges of Collaboration Across Europe In Congenital CardiacCare” . Ventripoint is very much part of this collaboration and issponsoring an Industrial Symposium with PD Dr. med. Kai Thorsten Laserspeaking about “Multi-Modality Assessment of the RV in PaediatricHeart Disease”. In particular, he will speak about his use of theVMS+ and its importance in the management and care of patients. Dr.Laser is the Deputy Director and Senior Physician from the Departmentof Pediatric Cardiology and Congenital Heart Defects of Herz-undDiabeteszentrium North Rhine-Westfalia | HDZ. Heis a leading cardiologist in the assessment ofcongenital heart disease using 2D/3D imaging. Assessment of right ventricular (RV) function is a challenge,especially in patients with congenital heart disease (CHD). Regularand accurate assessment of RV function is an integral part ofdiagnosing, planning treatment, and follow-up in such patients.
This year’s conference and symposium are particularlynotable for Ventripoint as we have transformed VMS+ into a productthat offers a valuable solution that can be applied for daily use byour customers. Further, we are exhibiting (Booth 4) and are usingthis opportunity to continue to maintain our efforts to connect withclinicians within the global congenital cardiology community and togrow our reach globally. Our focus for this year is on sales as wehave transitioned to a commercial operating company of which Europe isa particularly key market for the Ventripoint VMS+ products. Ourproducts facilitate a more efficient patient journey by providinginformation about the structure and function of the heart with anaccuracy equivalent to cardiac MRI at the time of the patient’sfirst echo scan. This detailed information, very early on in the carejourney, leads to improved quality of diagnosis, potentiallyshortening of the diagnosis time, and increasing efficacy of patientmanagement and care.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr. Jonathan Robinson
(416) 669-1001?
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.